SUPN — Expiration of Patent US12121523 related to QELBREE
Sep 4, 2029, 12:00:00 AM UTC
Summary
Patent US12121523 for QELBREE, a treatment for ADHD, expires on September 4, 2029. The patent protects a method utilizing a pharmaceutical agent that acts on serotonergic and noradrenergic transporters, providing strategic significance to Supernus Pharmaceuticals Inc. The expiration may open the market to generic alternatives, potentially impacting Supernus's revenue from this product.
Company
SUPERNUS PHARMACEUTICALS INC (SUPN)NASDAQ — Healthcare: Manufacturing, Drug Manufacturers - Specialty & Generic: Pharmaceutical Preparations
www.supernus.comSimilar Events
Patent US9603853 Expiration for QELBREE
The patent US9603853, relating to the product QELBREE by Supernus Pharmaceuticals Inc, is set to expire on February 7, 2033. This patent covers modified release formulations of viloxazine, a drug used to treat attention-deficit hyperactivity disorder (ADHD), along with methods for administering these formulations. The expiration may allow for increased competition from generic alternatives, potentially impacting Supernus's market position and revenue from QELBREE.
PatentPatent Expiration: QELBREE (US11458143)
The patent for QELBREE (US11458143), related to a treatment for ADHD using a pharmaceutical agent that acts on serotonergic and noradrenergic reuptake transporters and monoamine receptors, will expire on September 4, 2029. This expiration could lead to increased competition from generics, impacting Supernus Pharmaceuticals Inc.'s revenue from this product.
Patent ExpirationPatent Expiration for QELBREE (US9662338)
The patent US9662338 related to QELBREE, a modified release formulation of viloxazine developed by Supernus Pharmaceuticals Inc, is set to expire on April 2, 2035. The patent covers high-drug load formulations and methods of administering viloxazine, which may impact the product's market exclusivity and competitive positioning. Investors should note the potential for generic competition post-expiration, which could materially affect sales revenue for Supernus Pharmaceuticals.
Patent EventExpiration of Patent US10851377 for LEQVIO
The patent US10851377 for LEQVIO, assigned to Alnylam Pharmaceuticals Inc and Novartis Pharmaceuticals Corp, is set to expire on August 25, 2036. This patent covers methods for inhibiting the expression of the PCSK9 gene, which is significant for treating lipid disorders such as hyperlipidemia using RNA interference technology. The expiration of this patent may lead to increased competition in the market for lipid-altering therapies, potentially affecting the financial performance of the involved companies.
Patent ExpirationExpiration of Patent US8222222 related to LEQVIO
Patent US8222222 for LEQVIO, a therapeutic targeting the PCSK9 gene through double-stranded RNA, is set to expire on December 29, 2027. This expiration may impact the competitive landscape for LEQVIO, assigned to Alnylam Pharmaceuticals and Novartis Pharmaceuticals, by allowing potential generic competitors to enter the market. LEQVIO is known for its role in treating conditions related to elevated LDL cholesterol levels, making this patent expiration significant from a financial and strategic standpoint for both companies.
Patent ExpirationExpiration of Patent US9370582 for LEQVIO
The patent US9370582 for LEQVIO, assigned to Alnylam Pharmaceuticals Inc and Novartis Pharmaceuticals Corp, is set to expire on December 4, 2028. LEQVIO is an innovative drug designed to target specific RNA sequences, potentially altering gene expression related to various diseases. The expiration of this patent may allow for generic versions of the drug to enter the market, affecting proprietary sales and pricing strategies for both companies involved. Investors should monitor subsequent developments regarding generic competition following the patent's expiration.
Patent ExpirationExpiration of Patent US8809292 for LEQVIO
Alnylam Pharmaceuticals Inc and Novartis Pharmaceuticals Corp's patent US8809292 related to LEQVIO is set to expire on May 10, 2027. LEQVIO is a double-stranded ribonucleic acid (dsRNA) designed to inhibit the expression of the PCSK9 gene, which is associated with cholesterol regulation. The expiration of this patent may allow for increased competition in the market, potentially impacting revenue for the associated companies as generic versions could become available.
Patent ExpirationExpiration of Patent US12220408 for UBRELVY
The patent US12220408 for UBRELVY, a medication developed for the acute treatment of migraines, is set to expire on January 30, 2035. This patent, associated with Merck Sharp and Dohme LLC and AbbVie Inc., covers methods of administering ubrogepant, including considerations for patients with hepatic or renal impairment. The expiration of this patent may allow for the entry of generic versions of UBRELVY into the market, potentially impacting sales for the original product and influencing competitive dynamics in the migraine treatment sector.
Patent ExpirationExpiration of Patent US11925709 for UBRELVY
Merck Sharp and Dohme LLC and AbbVie Inc.'s patent US11925709 for UBRELVY, a medication designed to aid in the rapid disintegration of a drug compound within a polymer matrix, is set to expire on January 30, 2035. This expiration could have significant commercial implications, potentially allowing generic versions of the drug to enter the market, thereby affecting the revenue streams of both companies involved. The patent underscores the formulation's effectiveness in managing the active pharmaceutical ingredient (API).
Patent Expiration